Literature DB >> 16959611

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Silvia Di Agostino1, Sabrina Strano, Velia Emiliozzi, Valentina Zerbini, Marcella Mottolese, Ada Sacchi, Giovanni Blandino, Giulia Piaggio.   

Abstract

This article investigates the mechanistic aspects of mutant p53 "gain of function" in response to DNA damage. We show that mutant forms of p53 protein interact with NF-Y. The expression of cyclin A, cyclin B1, cdk1, and cdc25C, as well as the cdk1-associated kinase activities, is upregulated after DNA damage, provoking a mutant p53/NF-Y-dependent increase in DNA synthesis. Mutant p53 binds NF-Y target promoters and, upon DNA damage, recruits p300, leading to histone acetylation. The recruitment of mutant p53 to the CCAAT sites is severely impaired upon abrogation of NF-YA expression. Endogenous NF-Y, mutant p53, and p300 proteins form a triple complex upon DNA damage. We demonstrate that aberrant transcriptional regulation underlies the ability of mutant p53 proteins to act as oncogenic factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959611     DOI: 10.1016/j.ccr.2006.08.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  204 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

Authors:  Kang Liu; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

3.  NF-Y is necessary for hematopoietic stem cell proliferation and survival.

Authors:  Gerd Bungartz; Hannah Land; David T Scadden; Stephen G Emerson
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

4.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

5.  Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.

Authors:  Sergio Acin; Zhongyou Li; Olga Mejia; Dennis R Roop; Adel K El-Naggar; Carlos Caulin
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

Review 6.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

7.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

8.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

9.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.

Authors:  Kyoung-Hwa Lee; Mangmang Li; Aleksandra M Michalowski; Xinyue Zhang; Hongling Liao; Lingyi Chen; Yang Xu; Xiaolin Wu; Jing Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 10.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.